Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A

International Immunology

Volumn 13, Issue 5, 2001, Pages 625-632

  Markiewicz, Mary A ^a   Fallarino, Francesca ^a   Ashikari, Andrew ^a   Gajewski, Thomas F ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC2115 ^*  (United States)

Author keywords

Cross priming; Cytotoxic T lymphocytes; Dendritic cells; IL 12; Tumor immunity

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR PROTEIN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION;

EID: 0035002971     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/13.5.625     Document Type: Article

References (25)

1. Epitope spreading
2. The functional significance of epitope spreading and its regulation by co-stimulatory molecules
3. Functional evidence for epitope spreading in the relapsing pathology of EAE in the SJL/J mouse
4. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A)
5. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis
6. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis
7. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis
8. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
9. Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE
10. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: A comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade
11. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis
12. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
13. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
14. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
15. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
16. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
17. Dendritic cell/macrophage precursors capture antigen for MHC class I presentation by dendritic cells
18. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against P1A-encoded tumor antigen
19. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
20. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815
21. Tumor rejection requires CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7- 2 for active tumor immunization
22. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
23. Epitope spreading: Lessons from autoimmune skin diseases
24. Stepwise immunologic selection of antigenic variants during tumor growth
25. Differences in antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection